Factors predicting the failure of interruption of highly active antiretroviral treatment (HAART) in HIV-infected patients;Factores que predicen el fracaso de las interrupciones del tratamiento antirretroviral (TAR) en los pacientes con infección por el VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 4, 2005, Pages 202-207

  Cervero Jiménez, Miguel ^a,b   Torres Perea, Rafael ^a   Ruiz Capillas, Juan José ^a   Del Álamo, Manuel ^a   Agud, José Luis ^a   Solís, Javier ^a   Bouzas, Elisa ^a  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b NONE   (Spain)

Author keywords

Predictive model; Prognostic factor; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG INTERMITTENT THERAPY; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; ROC CURVE; TREATMENT FAILURE;

EID: 17644423414     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073145     Document Type: Article

References (13)

1. Carr A, Cooper DA. Adverse effects of antiretroviral of antirretroviral therapy. Lancet. 2000;356:1423-30.
2. Bozzzette SA, Ake CE, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for Human Immunodeficiency Virus Infection. N Engl J Med. 2003;348:702-10.
3. García F. Interrupciones estructuradas del tratamiento antirretroviral: ¿una nueva estrategia terapéutica? Enferm Infecc Microb Clin. 2002;20:373-5.
4. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-80.
5. Yerly S, Fagard C, Günthard H, Hirschel and the Swiss IIV Cohort Study. Drug resistance mutations during structuraded treatment interruptions. Antiviral Therapy. 2003;8:411-5.
6. Metzner K, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structures treatment interruptions. J Infect Dis. 2003;188:1433-43.
7. th EACS October 2003 [Abstract 7.6/4].
8. Hernangómez S, Prazuk T, Cosin J, Hocqueloux L, DeLucas K, López Bernaldo de Quirós JC. Suspensión del tratamiento antirretroviral (TAR) en pacientes con infección por VIH con un buen control de la replicación vírica y buena reconstitución inmune tras el tratamiento. XI Congreso SEIMC Mayo 2004 [Abstract 470].
9. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cells: a controlled, prospective trial. AIDS. 2004;18:439-46.
10. Amador C, Ena J, Pasquau F, Benito C, Ruiz de Apodaca RF. Interrupciones prolongadas de tratamiento antirretroviral según respuesta de linfocitos CD4+. XI Congreso SEIMC Mayo 2004 [Abstract 472].
11. Rivero A, Santos J, Cisneros JM, Pujol E, Camacho A, Márquez M, et al. Seguridad de una estrategia de interrupción prolongada del tratamiento antirretroviral (IPT) guiada por las cifras de linfocitos CD4+ y factores predictivos de su fracaso. XI Congreso SEIMC Mayo 2004 [Abstract 473].
12. rd ICCAC September 2003 [Abstract H-856].
13. Poulton MB, Sabin C, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS. 2003;17:126-8.